Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Dave Coulier reveals he has tongue cancer, his 2nd diagnosis in a year, after beating non-Hodgkin lymphoma - 2Material of Innovativeness: A Survey of \Releasing Your Imaginative Potential\ Online Workmanship Course
- 3Mystery foot suggests a second early human relative lived alongside Lucy
- 4Moscow accuses Berlin of stifling the opposition
- 5Best bar-b-que Style: Which One Is Your Number one?
- The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
- The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- 10 Moving Design Frill for Summer 2023
- Find Your Ideal Tea: Six Particular Assortments
- IDF says up to 90% of Iran’s weapons industry could be hit within days
- Nexi expands alliance with PayPal
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- Rubble, mud and hair: How to rebuild a home in Gaza
- Step by step instructions to Protect Your Retirement with Senior Protection.
